CN113203808A - Detection method of fire therapy liniment - Google Patents
Detection method of fire therapy liniment Download PDFInfo
- Publication number
- CN113203808A CN113203808A CN202110455689.7A CN202110455689A CN113203808A CN 113203808 A CN113203808 A CN 113203808A CN 202110455689 A CN202110455689 A CN 202110455689A CN 113203808 A CN113203808 A CN 113203808A
- Authority
- CN
- China
- Prior art keywords
- liniment
- methanol
- solution
- extracting
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940040145 liniment Drugs 0.000 title claims abstract description 54
- 239000000865 liniment Substances 0.000 title claims abstract description 54
- 238000001514 detection method Methods 0.000 title claims abstract description 31
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 235000008995 european elder Nutrition 0.000 claims abstract description 14
- 241000208829 Sambucus Species 0.000 claims abstract description 13
- 235000018735 Sambucus canadensis Nutrition 0.000 claims abstract description 13
- 235000007123 blue elder Nutrition 0.000 claims abstract description 13
- 235000007124 elderberry Nutrition 0.000 claims abstract description 13
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 12
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 11
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims abstract description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000006264 Asimina triloba Nutrition 0.000 claims abstract description 9
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 9
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940116229 borneol Drugs 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 244000189799 Asimina triloba Species 0.000 claims abstract description 7
- 241001530884 Gynura segetum Species 0.000 claims abstract description 7
- 239000009685 tusanqi Substances 0.000 claims abstract description 7
- 241000242759 Actiniaria Species 0.000 claims abstract description 4
- 241000929011 Illicium simonsii Species 0.000 claims abstract description 3
- 240000007311 Commiphora myrrha Species 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 27
- 239000012085 test solution Substances 0.000 claims description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 8
- HVTPIQKJZSQSLM-UHFFFAOYSA-N cimicidine Natural products C12=CC=C(OC)C(O)=C2N(C(=O)CC)C2C11CCN(CCC3)C41OC(=O)CC43CC2 HVTPIQKJZSQSLM-UHFFFAOYSA-N 0.000 claims description 6
- 235000008708 Morus alba Nutrition 0.000 claims description 5
- 240000000249 Morus alba Species 0.000 claims description 5
- 239000013558 reference substance Substances 0.000 claims description 5
- CTGSUWSGSNKTPS-UHFFFAOYSA-N cyclohexane;ethyl acetate;methanol Chemical compound OC.CCOC(C)=O.C1CCCCC1 CTGSUWSGSNKTPS-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000012088 reference solution Substances 0.000 claims description 3
- 230000005526 G1 to G0 transition Effects 0.000 claims description 2
- FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000004809 thin layer chromatography Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 239000013642 negative control Substances 0.000 description 18
- 238000011160 research Methods 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000007689 inspection Methods 0.000 description 11
- 240000009023 Myrrhis odorata Species 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- -1 linarin glycoside Chemical class 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 6
- 229930182470 glycoside Natural products 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000092728 Eleutherococcus gracilistylus Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 244000028419 Styrax benzoin Species 0.000 description 3
- 235000000126 Styrax benzoin Nutrition 0.000 description 3
- 235000008411 Sumatra benzointree Nutrition 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 229960002130 benzoin Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000019382 gum benzoic Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 244000182644 licorice root Species 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- ZUPHXNBLQCSEIA-UHFFFAOYSA-N 1-methyl-tetrahydro-beta-carboline-3-carboxylic acid Natural products N1C2=CC=CC=C2C2=C1C(C)NC(C(O)=O)C2 ZUPHXNBLQCSEIA-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 240000006432 Carica papaya Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241000720991 Illicium Species 0.000 description 2
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 241001057584 Myrrha Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 240000004760 Pimpinella anisum Species 0.000 description 2
- 235000012550 Pimpinella anisum Nutrition 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 241001050737 Sambucus williamsii Species 0.000 description 2
- 241001180876 Saposhnikovia Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- DCYOADKBABEMIQ-OWMUPTOHSA-N myricitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1=O DCYOADKBABEMIQ-OWMUPTOHSA-N 0.000 description 2
- DCYOADKBABEMIQ-FLCVNNLFSA-N myricitrin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1=O DCYOADKBABEMIQ-FLCVNNLFSA-N 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229930015704 phenylpropanoid Natural products 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- AWOGQCSIVCQXBT-LATRNWQMSA-N (+)-Fargesin Natural products C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C4OCOC4=CC=3)[C@@H]2CO1 AWOGQCSIVCQXBT-LATRNWQMSA-N 0.000 description 1
- MHXCIKYXNYCMHY-AUSJPIAWSA-N (+)-lariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 MHXCIKYXNYCMHY-AUSJPIAWSA-N 0.000 description 1
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000003377 Allium tuberosum Species 0.000 description 1
- 235000005338 Allium tuberosum Nutrition 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000208229 Burseraceae Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 240000000425 Chaenomeles speciosa Species 0.000 description 1
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000068485 Convallaria majalis Species 0.000 description 1
- 235000009046 Convallaria majalis Nutrition 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- LIOOJQZRNLJKMU-UHFFFAOYSA-N Demethyl coniferin Natural products OCC=Cc1ccc(OC2OC(CO)C(O)C(O)C2O)c(O)c1 LIOOJQZRNLJKMU-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000000836 Epigaea repens Nutrition 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- AWOGQCSIVCQXBT-LYDRAKHJSA-N Fargesin Chemical compound C1=C(OC)C(OC)=CC=C1[C@@H]1[C@H](CO[C@H]2C=3C=C4OCOC4=CC=3)[C@H]2CO1 AWOGQCSIVCQXBT-LYDRAKHJSA-N 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241001431818 Gynura japonica Species 0.000 description 1
- 240000008672 Gynura procumbens Species 0.000 description 1
- 235000018457 Gynura procumbens Nutrition 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007232 Illicium verum Species 0.000 description 1
- 235000008227 Illicium verum Nutrition 0.000 description 1
- 241001122006 Incarvillea arguta Species 0.000 description 1
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 description 1
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-WPRPVWTQSA-N L-Ephedrine Natural products CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- 240000000161 Lagerstroemia indica Species 0.000 description 1
- YVRYZXAHRGGELT-UHFFFAOYSA-N Lariciresinol Natural products C1=C2OCOC2=CC(C2C(C)C3(OC)C=C(CC=C)C(=O)CC3(O2)OC)=C1 YVRYZXAHRGGELT-UHFFFAOYSA-N 0.000 description 1
- 241000229182 Ledebouriella seseloides Species 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 241000228153 Penicillium citrinum Species 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001621801 Rohdea chinensis Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 240000006831 Rubus chamaemorus Species 0.000 description 1
- 235000016554 Rubus chamaemorus Nutrition 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 235000003142 Sambucus nigra Nutrition 0.000 description 1
- 240000006028 Sambucus nigra Species 0.000 description 1
- 241001180873 Saposhnikovia divaricata Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- SOSLMHZOJATCCP-AEIZVZFYSA-N afzelin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O SOSLMHZOJATCCP-AEIZVZFYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- SFLMUHDGSQZDOW-FAOXUISGSA-N coniferin Chemical compound COC1=CC(\C=C\CO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-FAOXUISGSA-N 0.000 description 1
- LIOOJQZRNLJKMU-UXXRCYHCSA-N coniferin Natural products OCC=Cc1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(O)c1 LIOOJQZRNLJKMU-UXXRCYHCSA-N 0.000 description 1
- SFLMUHDGSQZDOW-IBEHDNSVSA-N coniferoside Natural products COC1=CC(C=CCO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-IBEHDNSVSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KUSXBOZNRPQEON-ONEGZZNKSA-N dehydrodiconiferyl alcohol Chemical compound O1C=2C(OC)=CC(\C=C\CO)=CC=2C(CO)C1C1=CC=C(O)C(OC)=C1 KUSXBOZNRPQEON-ONEGZZNKSA-N 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- IKUQEFGEUOOPGY-UHFFFAOYSA-N euoniside Natural products COC1=CC=2C=CC(=O)OC=2C(OC)=C1OC1OC(CO)C(O)C(O)C1O IKUQEFGEUOOPGY-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002214 flavonoid derivatives Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 235000006826 lariciresinol Nutrition 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- AWOGQCSIVCQXBT-UHFFFAOYSA-N methyl piperitol Natural products C1=C(OC)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 AWOGQCSIVCQXBT-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- JYFOSWJYZIVJPO-UHFFFAOYSA-N pseudolaroside B Natural products COC1=CC(C(O)=O)=CC=C1OC1C(O)C(O)C(O)C(CO)O1 JYFOSWJYZIVJPO-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a detection method of a fire therapy liniment, and the raw material medicines of the liniment comprise cortex acanthopanacis, myrrh, radix sileris, pawpaw, cortex mori radicis, rhizoma anemones raddeanae, gynura segetum, elderberry, illicium simonsii and borneol; mainly comprises thin layer chromatography and UPLC detection. The method can detect various medicinal materials and main components in the fire therapy liniment, thereby providing a basis for quality standard control of the fire therapy liniment and bringing positive significance to the popularization of the liniment.
Description
Technical Field
The invention relates to the field of national medicines and quality detection thereof.
Background
The fire therapy technology is formed by collecting characteristics of the Yi nationality and improving the technology, firstly spraying the medicine of the Yi nationality formula on a treatment part, covering wet gauze, then spraying medicinal liquor on the gauze, igniting the gauze by using a lighter, extinguishing the burning gauze when a patient can not bear high temperature, repeatedly operating for 3-5 times after one minute, and realizing the optimal effect of flushing skin at the treatment part and the effects of activating blood and relieving pain.
The Yi-nationality medical hospital in the Liangshan-Zhou-combined Hospital has a clinical experience prescription for many years, which comprises troops (cortex acanthopanacis), kojiu soil (myrrh), Wabuyou (two hairs), Szechwan-Chinen (ramulus Sambuci Williamsii), radix frontal (illicium verum), Erlesei-ben (radix sileris), Chubu (pawpaw), fructus zanthoxyli (cortex mori radicis), lamogger (gynura segetum) and borneol. The empirical formula is usually soaked to obtain liniment. The liniment has the main functions: promoting blood circulation, removing blood stasis, relieving pain, and treating pain, numbness and swelling of neck, waist, leg and knee joint caused by pathogenic wind-cold-dampness and strain, rheumatism, gout, scapulohumeral periarthritis, fasciitis, and gonarthritis. Spraying the medicinal liquid on affected part, wiping with palm, spraying the medicinal liquid on gauze for wet application of pain part 2-5 times per day, or applying medicinal liquid for Yi medical extraction and suction, and fire therapy. The fire therapy liniment has simple processing technology and convenient use, no toxic or side effect is found, the clinical application in Yi medicine hospitals of Chinese and western medicine combination hospitals in Liangshan is more than 5 years, the number of cases is more than 5000, and the total effective rate reaches 91.02%.
However, the liniment has no related quality research, and has certain restriction on the use and popularization of the product.
Disclosure of Invention
Therefore, the invention aims to provide a detection method capable of effectively controlling a fire therapy liniment.
Specifically, the invention provides a detection method of a fire therapy liniment, and the raw material medicines of the liniment comprise cortex acanthopanacis, myrrh, radix sileris, pawpaw, cortex mori radicis, rhizoma anemones raddeanae, gynura segetum, elderberry, illicium simonsii and borneol; it comprises the UPLC detection content of the cimicidin:
using the cimicidin as a reference substance; the detection wavelength is 325 nm;
a chromatographic column: c18 as stationary phase
Mobile phase: acetonitrile: 0.05 to 0.2 percent of phosphoric acid
Wherein the phosphoric acid concentration may be selected from 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.20%, and the like.
The raw material medicaments can be prepared from the following components in percentage by weight:
the dimensions of the column were as follows: 2.1X 100mm, 1.8 μm.
Wherein, the preparation of the test solution in the UPLC comprises the following steps: drying liniment, and extracting with methanol.
In the preliminary experiment, various UPLC detection conditions are adopted for detection, but the separation effect of the cimicidin is poor, for example:
a is acetonitrile: 0.1% phosphoric acid:
as a result: is not separated from the rear peak and the front peak (see the attached drawings of the specification)
B. Acetonitrile: 0.1% phosphoric acid
As a result: not separated from the preceding peak
C. Acetonitrile: 0.1% phosphoric acid
As a result: not separated from the following peak
Therefore, the invention finally selects the chromatographic conditions capable of realizing effective separation of the linarin glycoside through a large amount of experimental screening:
acetonitrile: 0.05 to 0.2 percent of phosphoric acid
Wherein, it also includes the thin layer content of elderberry:
(1) collecting liniment, removing solvent, and dissolving the residue with methanol to obtain test solution;
(2) extracting ramulus Sambuci Williamsii reference medicinal material by liniment preparation method, removing solvent from the extractive solution, and extracting with methanol to obtain ramulus Sambuci Williamsii reference medicinal material solution;
(3) the gel was developed on silica gel G thin layer plates with cyclohexane-ethyl acetate-methanol ═ 6:2: 1.
With the method, compound spots can be effectively spread, so that elderberry can be effectively detected in the liniment. In the former period, the inventor also uses other detection methods, such as the standard of traditional Chinese medicinal materials in Yunnan province, cyclohexane-ethyl acetate-methanol is 3: 1: 0.5, however, the sample solution was still at the origin and could not be developed.
Wherein, it also includes the thin layer detection content of the mulberry bark:
(1) collecting liniment, removing solvent, and dissolving the residue with methanol to obtain test solution;
(2) extracting cortex Mori with reference to the liniment preparation method, removing solvent from the extractive solution, and extracting with methanol to obtain cortex Mori reference solution;
(3) chloroform-methanol 5:1 was applied to silica gel G thin layer plates.
By using the method, compound spots can be effectively spread, so that the cortex mori radicis can be effectively detected in the liniment. In the former period, the inventor also uses other detection methods, such as Liu Yi culvert, and the like, quality detection and quality standard of the cortex mori radicis medicinal material, Ji head university newspaper (Nature science edition), 2019,40(05):45-52. ", and dichloromethane-ethyl acetate-methanol-glacial acetic acid (1: 6: 2.5: 1), but the test article cannot be effectively developed.
Wherein, it also includes the thin layer detection content of cortex acanthopanacis:
(1) removing solvent from liniment, extracting with water-chloroform solvent system, removing volume of chloroform extractive solution, and dissolving with methanol to obtain test solution;
(2) taking a cortex acanthopanacis reference medicinal material, extracting according to the preparation method of the liniment, and preparing a cortex acanthopanacis reference medicinal material solution according to the content in the step (1);
(3) chloroform-methanol was applied at 21:1 on silica gel G thin layer plates.
Cortex acanthopanacis: pungent and warm in property and bitter in taste. It enters liver and kidney meridians. Has the functions of dispelling wind and eliminating dampness, tonifying liver and kidney, strengthening tendons and bones, inducing diuresis and relieving swelling. Shen nong Ben Cao Jing: "treating hernia and abdominal pain, benefiting qi for , it is impossible for children to treat ulcer and erosion of the yin. "miscellaneous records of famous physicians": the traditional Chinese medicine composition mainly treats impotence of men's yin, dampness under the sac, dribbling urine, pruritus vulvae and pain of waist and back of women, pain and numbness of both feet and wind weakness, tonifying middle-jiao and replenishing vital essence, strengthening muscles and bones, strong will, long-time taking, light weight and aging resistance. "modern pharmacology: cortex Acanthopanacis has antiinflammatory, analgesic, tranquilizing, blood serum antibody concentration increasing, mononuclear macrophage phagocytic function promoting, anti-stress, nucleic acid synthesis promoting, blood sugar lowering, sex hormone-like, anti-tumor, anti-mutagenesis, antiulcer, and anti-rejection effects.
Myrrh: pungent, bitter and mild. It enters heart, liver and spleen meridians. Dispel stasis, relieve pain, resolve swelling and promote tissue regeneration. Can be used for treating thoracic obstruction, cardialgia, gastralgia, dysmenorrhea, amenorrhea, puerperal stagnation, abdominal mass, rheumatalgia, traumatic injury, carbuncle, swelling, and pyocutaneous disease. Myrrh comes from "the book of the herbal drawing" (the book of changes of the materia Medica): myrrh, raw Persian, all the countries of the south of the jin Hai and Guangzhou. The roots and the plants of wood are like olive and green and dense leaves, and the old people have the paste liquid dripping underground and congealing into blocks, which are large or small, and like benzoin. The term "marine herbs" is: "follow Xuzhu nan Zhou Ji": shengbosu, pine resin in their place, is like Shenxiang red black. "Kaibao materia Medica" (Kaibao): "Shengbosu, similar to benzoin, has variable block size and is black. The book's herbal drawing is recorded: myrrh, raw Persian. Jin Hai nan all countries and Guangzhou. The roots of wood are like olive and dense leaves, and the old people have the paste and liquid dripping underground and congealing into blocks, large or small, like benzoin, and the collection is not repeated. "compendium" is listed: according to Yi Tong Zhi from Yi Tong Zhi, Mo Yao is as tall as pine, thick as one inch, when digging out the lower part of the tree, it is cut down with an axe, and the resin flows to the bank, the ten heaven. "conform to the imported myrrh as above. Modern pharmacology: the main chemical components of myrrh include monoterpene, sesquiterpene, triterpene, steroid and lignin. Pharmacological research shows that the myrrh has pharmacological activity in many aspects such as defervescence, anti-inflammation, analgesia, neuroprotection and the like, and has no obvious toxic or side effect.
Wind prevention: pungent and sweet with mild temperature. It enters bladder, liver and spleen meridians. Dispel wind and relieve exterior syndrome, subdue dampness and alleviate pain, stop spasm. Can be used for treating common cold, headache, rheumatalgia, rubella, pruritus, and tetanus. It is mainly caused by strong wind, dizziness, headache, aversion to wind, wind pathogen, blindness, wind moving around the body, arthralgia and arthralgia. (Yu Shu (imperial Explanation) with pain), restlessness. Can lighten the body after long-term use. A Chinese name of Cuyun (Miscant from Yu Shu). Shengchuan ze. Wu pu (wu pu) is recorded as follows: divaricate saposhnikovia root, cloudberry, lemongrass, roots, allium tuberosum, hundreds of species, shennong huangdi qi bertong jun leigong magpie, which is sweet and nontoxic, Lishi xian, or Japanese handan shancai, Zhengyue leaf, thin circle, black, yellow and white, May flower yellow, June black, Rohdea chinensis, sun stem, and Lang Han Lian (imperial view). Famous physicians' stand: an anise, a baizhi, a pingfeng, an root, a baichai, a raw flatstem milkvetch, and a handan, an enamel evil, a shancai, a root of May-February, and a fierce dryout. Table "paradigm ran" cloud: fang Feng is good at three auxiliary herbs and Bai is good at. Modern pharmacology: the divaricate saposhnikovia root mainly contains chemical components such as chromone, coumarins, acidic polysaccharide and the like, and can achieve the effects of relieving fever and easing pain by influencing the expression of in-vivo fever inflammatory factors and the release of related pain factors; the antibacterial and anti-inflammatory effects are achieved by inhibiting the generation of related inflammatory factors or inflammatory mediators; the anti-allergic effect is achieved by reducing the expression of related anti-allergic factors; the anti-tumor effect is achieved by inhibiting the growth of related tumor factors; the function of improving the immunity of the organism is achieved by selectively increasing macrophage release related factors.
Pawpaw: acid, warm. It enters liver and spleen meridians. Relaxing tendons and activating collaterals, regulating stomach function and eliminating dampness. Can be used for treating damp arthralgia, spasm, soreness and pain of waist and knee joint, summer dampness vomiting and diarrhea, spasm pain of tendon, loempe, and edema. Modern pharmacology: the chemical components in the pawpaw mainly comprise saccharides, flavonoids, organic acids, terpenoids, volatile oil and biological enzyme substances, and the pawpaw tea has the effects of calming the liver, harmonizing the stomach, relaxing tendons, activating collaterals, protecting the liver, resisting bacteria, diminishing inflammation, dispelling wind-damp, resisting oxidation and the like.
White mulberry root-bark: sweet and cold in nature. It enters lung meridian. Purge lung, relieve dyspnea, induce diuresis to alleviate edema. Can be used for treating cough and asthma due to lung heat, edema, fullness, oliguria, and edema of face, eye and skin. Treatise on herb Property: it is indicated for lung qi dyspnea with distention and edema of water and dampness, mainly impairing the function of body fluid, promoting diuresis, relieving edema, consumptive disease, fever, headache and internal deficiency. "compendium of materia Medica": sang Bai Pi is good at inducing diuresis and draining excess syndrome. Therefore, it is advisable for the lung to contain water and qi and the lung to have the rest fire. "modern pharmacology: the product contains various flavonoid derivatives, such as sanguirin, sanguichromene, sanguirin, etc.; umbelliferone, scopoletin, and antihypertensive component similar to acetylcholine; in addition, mulberry bark furan A is extracted. The product has effects in relieving cough, promoting urination, and increasing urine output and sodium, potassium and chloride output; the decoction and the extracts of ethanol, ether and methanol thereof have the function of reducing blood pressure to different degrees; has tranquilizing, anticonvulsive, analgesic, and cooling effects on nervous system; has exciting effect on intestine and uterus. The decoction has effect in inhibiting Staphylococcus aureus, Bacillus typhi and Bacillus dysenteriae. The product has inhibitory effect on cervical cancer JTC28 and lung cancer cells, and recent research also shows that the product also has anti-HIV effect.
The two-head hair contains a plurality of chemical components, and compounds such as monoterpene, iridoid, sesquiterpene, triterpene, steroid, alkaloid, flavone, amide, phenylpropanoid and the like are separated from the root stem or the overground part of the two-head hair at present. The extractive or the chemical components contained in the extractive have the functions of promoting cell differentiation, resisting inflammation, resisting bacteria and oxidation, preventing and treating cholelithiasis, and the like, and has obvious curative effect when being clinically used for treating hepatitis, lithiasis and the like. The chloroform extract of the double-head hair has anti-inflammatory effect, which may be the reason for the double-head hair used for treating rheumatic bone pain, swelling, furuncle and various infectious diseases, so the chloroform extract may be the effective part of the anti-inflammatory and antipyretic effects of the double-head hair. The two hairs have the obvious effect of reducing serum transaminase and have the protective effect on liver injury caused by carbon tetrachloride, so the toilet flower tablet (containing ursolic acid 75%) used by the liberation military 45 hospital and other units has the obvious curative effect of treating acute viral hepatitis and high cure rate. The two-head hair has bacteriostasis to various pathogenic bacteria, especially to staphylococcus aureus, and has obvious curative effect on upper respiratory tract, urinary system, gastrointestinal tract and other infectious diseases clinically. The antibacterial active ingredient is alkaloid component
The pseudo-ginseng has various chemical components, and the research parts are mainly concentrated on stems and leaves. The separated and identified chemical components comprise flavonoids, phenolic acids, alkaloids, terpenes, phenylpropanoids, fatty acids, steroids and glycosides thereof. The gynura segetum has the effect of resisting gout, and a mouse hyperuricemia experiment, a mouse writhing experiment and a mouse ear swelling experiment show that the gynura segetum can obviously reduce the mouse serum uric acid level, the writhing frequency caused by glacial acetic acid stimulation and the mouse ear swelling degree caused by dimethylbenzene, and the gynura segetum alcohol extract has the obvious effect of resisting gout
Ramulus Sambuci Williamsii contains ursolic acid, oleanolic acid, gallic acid, rutin, quercetin, protocatechuic acid, and morroniside. Is prepared from Chuan-xiong rhizome, 3-carboxychuanxiong rhizome, 1,2,3, 4-tetrahydro-1-methyl-beta-carboline-3-carboxylic acid, salidroside, 4-hydroxybenzyl-beta-D-glucoside, 4-hydroxy-1- (2-hydroxyethyl) -phenyl-3-O-beta-D-glucopyranoside, coniferin, vanillic acid-4-O-beta-D-glucopyranoside, isorhamnetin-3-O-beta-D-rutinoside, etc. The elderberry has obvious effect on repairing bone density, is beneficial to bone growth and bone content increase of thighbone and shinbone, has obvious inhibition effect on permeability increase of capillary vessels in abdominal cavity of the elderberry, and prompts that stem branches of the elderberry have obvious analgesic and anti-inflammatory effects. The research result shows that the lariciresinol separated from the methanol extract of the elderberry stem and branch shows the antifungal activity by interfering the cell membrane of fungi, and can be used as a novel antifungal agent for treating fungal infection diseases of human beings.
The wild anise contains de-4 '-O-methylylangambin, fargesin, 3' -O-demethyllepiperonesoxim, lariciresinioldimethyl ether, dehydrodiconiferol, myricetin-3-O-alpha-L-rhamnoside, kaempferol, quercetin, kaempferin 3-O-alpha-L-rhamnoside, quercetin-3-O-alpha-L-rhamnopyranosyl (1 → 6) -beta-D-glucopyranoside, etc. the modern research shows that the wild anise contains the compound of de-4 '-O-methylylangamin, 3' -O-demethyl ionol, laricinoldimethyl ether, and the compound of dehydrodicentriperonol, myricetin-3-O-alpha-L-rhamnoside. Is widely applied to traumatic hemorrhage, abdominal distention and emesis, traumatic injury, rheumatoid arthritis and other diseases, and has high medical value. The aniseed medicinal plant has strong bacteriostatic activity and has bacteriostatic effects on various strains: typhoid bacillus, diphtheria bacillus, dysentery bacillus, aspergillus flavus, penicillium citrinum, aspergillus niger, bacillus subtilis, escherichia coli and staphylococcus aureus. In addition, the illicium genus medicinal plant has anti-inflammatory, analgesic and antioxidant activities.
The method can detect various medicinal materials and main components in the fire therapy liniment, thereby providing a basis for quality standard control of the liniment and bringing positive significance to popularization of the liniment.
Drawings
FIG. 1 UPLC chromatogram of control
FIG. 2 UPLC chromatogram of test sample
FIG. 3 negative control UPLC chromatogram
FIG. 4 is a thin layer chromatogram of Acanthopanax senticosus, in which 1: sample 2: acanthopanax contrast medicinal material 3: isofraxidin control 4: negative control
FIG. 5 Saposhnikovia divaricata thin layer chromatogram, in which 1-3: sample 4: radix sileris reference medicinal material 5: cimicidin control 6: 5-0-methylvisammioside control 7: negative control
FIG. 6 is a thin layer chromatogram of cortex Mori, wherein 1-3: sample 4: cortex Mori control 5 negative control
FIG. 7 Sambucus nigra thin layer chromatogram, wherein 1-3: sample 4: elderberry control medicinal material 5 negative control
FIG. 8 UPLC chromatogram of mobile phase Condition A
Detailed Description
The raw materials used in the examples were as follows:
cortex Acanthopanacis Radicis is the dried root bark of Acanthopanax gracilistylus (Dunn) S.Y.Hu of Araliaceae. The quality standard of the raw materials (medicinal materials) for research and medication is checked to be in accordance with relevant regulations under 67 pages of Chinese pharmacopoeia (2020 edition I).
Myrrha, this product is dried resin of Comiphora myrrha Engl. or Comiphora molmol Engl. of Burseraceae. It should comply with the relevant regulations under 199 pages of the Chinese pharmacopoeia (2020 edition I). The quality standard of the raw materials (medicinal materials) for research and medication is met through inspection.
The rhizoma anemones Raddeanae is dry whole plant of Lagerstroemia indica Incarvillea arguta (Royle) Royle. It should meet the relevant regulations under 55 pages of the standards for Chinese medicinal materials in Yunnan province (2005 edition, fourth volume, Yi nationality medicine II). The quality standard of the raw materials (medicinal materials) for research and medication is met through inspection.
Sambucus williamsii Hance is dried stem and leaf of Sambucus williamsii Hance of Caprifoliaceae. It should meet the relevant regulations under page 91 of the standards for Chinese medicinal materials in Yunnan province (2005 edition of the second book Yi nationality medicine). The quality standard of the raw materials (medicinal materials) for research and medication is met through inspection.
Wild anise, which is the dried root bark and stem bark of the Magnoliaceae family, Illicium angustifolium lancelebratum A.C. Smith. All the year round, plucked and dried. It should meet the relevant regulations under page 13 of Zhejiang province Chinese medicinal material Standard (2017 edition-first book). The quality standard of the raw materials (medicinal materials) for research and medication is met through inspection.
Radix Saposhnikoviae, which is dried root of SaposhnikobaPiperivacatala (Turcz.) Schischk. It should comply with the relevant regulations under 159 pages of the "Chinese pharmacopoeia" (2020 edition I). The quality standard of the raw materials (medicinal materials) for research and medication is met through inspection.
Cortex Mori, which is the dried root bark of Morus alba L. The quality standard of the raw materials (medicinal materials) for research and medication is determined to be in accordance with the relevant regulations under the Chinese pharmacopoeia (2020 edition, part I319).
Pawpaw, a dry nearly mature fruit of chaenomeles speciosa (sweet) Nakai of Rosaceae, should meet the requirements of the Chinese pharmacopoeia (2020 edition one) at page 63. The quality standard of the raw materials (medicinal materials) for research and medication is met through inspection.
Gynura procumbens (lour.) Merr, dried root tuber of Gynura japonica (Thunb) Juel of Compositae. It should meet the relevant regulations under 87 pages of the standards for Chinese medicinal materials in Yunnan province (2005 edition of the second book Yi nationality medicine). The quality standard of the raw materials (medicinal materials) for research and medication is met through inspection.
Borneol, RNEOLUM SYNTHETIC
CioHisO 154.2
It should comply with the relevant regulations under 199 pages of the Chinese pharmacopoeia (2020 edition I). The quality standard of the raw materials (medicinal materials) for research and medication is met through inspection.
Example 1
Cutting other medicinal materials except the borneol into pieces for later use; adding Borneolum Syntheticum, heating and refluxing with 60% ethanol for 5 hr, filtering to remove the extractive solution, shaking, and standing in the shade to obtain liniment.
Example 2
Cutting other medicinal materials except the borneol into pieces for later use; adding Borneolum Syntheticum, extracting with 56% (v/v) Chinese liquor for 2 hr under ultrasonic assistance, extracting for 3 times, filtering to remove the extractive solution, shaking, and standing in the shade to obtain liniment.
EXAMPLE 3 Ramarioside content determination
1. Chromatographic conditions and System suitability test
Chromatographic Column ACQUITY UPLCHSS C18 chromatographic Column (2.1X 100mm Column, 1.8 μm); mobile phase acetonitrile-0.1% phosphoric acid solution (V/V); the detection wavelength is 325 nm; the flow rate is 0.2 mL/min; the column temperature is 30 ℃; the sample injection amount is 2 muL. Under the chromatographic condition, the number of theoretical plates is not less than 2000 in terms of chlorogenic acid peak.
Mobile phase conditions:
the chromatogram is shown in FIGS. 1-3.
2. Preparation of test solution
Collecting liniment, precisely weighing, removing solvent, drying, adding methanol, extracting under supercritical reflux for 30min, and filtering to obtain extractive solution as test solution.
3. Preparation of control solutions
7.02mg of the linarin control was accurately weighed and dissolved in methanol to prepare a 0.702mg/mL standard solution as a control solution.
4 linear relationship investigation
Precisely sucking 1mL of reference stock solution (mass concentration of 0.702mg/mL) respectively, placing in a 5mL volumetric flask, adding methanol to a constant volume, shaking up, sequentially taking 1mL of constant volume step by step, wherein the mass concentrations are 0.7020mg/mL, 0.1404mg/mL, 0.0280mg/mL, 0.0056mg/mL and 0.0011mg/mL respectively, filtering through a microporous membrane, carrying out sample injection determination according to a proposed chromatographic condition, and recording peak area. Drawing a standard curve by taking the l-ephedrine glycoside sample injection concentration (C) as an abscissa and taking a chromatographic peak area value (Y) as an ordinate to obtain a regression equation Y which is 12,376,023x +24,720R20.9999(n 5). The result shows that the linear relation between the area of the peak and the area of the linarin glycoside is good in the range of 0.0011mg/ml to 0.7020 mg/ml.
5 precision test
Precisely sucking a proper amount of 2.6.3 reference substance solution, continuously and repeatedly injecting sample for 6 times according to the drawn chromatographic conditions, measuring by the method, and recording the peak area. As a result, the RSD of the area of the region of the L-ephedrine glycoside peak was 0.19% (n-6), indicating good precision of the apparatus.
6 stability test
Precisely sucking the same sample solution, respectively carrying out sample injection measurement at 0, 1,2, 4, 8, 12 and 24h, and recording peak area. As a result, the RSD of the area of the l-ephedrine glycoside peak was 0.27% (n-6), indicating that the test solution was stable within 24 hours.
7 repeatability test
Taking a proper amount of samples of the same batch, precisely weighing, preparing 6 parts of test sample solutions in parallel according to a method, and injecting samples according to drawn-up chromatographic conditions for determination. RSD was 1.49% (n ═ 6), indicating good reproducibility of the method.
8 sample recovery test
Taking a proper amount of 6 samples with known content, respectively and precisely adding reference substances, preparing a sample solution according to a method, carrying out sample injection measurement according to drawn-up chromatographic conditions, recording peak areas, and calculating the sample injection recovery rate. The results are shown in Table 1.
TABLE 1 recovery test
9 sample content determination
Taking 6 batches of samples, preparing a test solution according to a method, carrying out sample injection measurement according to drawn-up chromatographic conditions, recording peak areas, and calculating the content of the glucoma-roside. As a result, the content of the linarin in 6 samples was 0.0576mg/g, 0.0526mg/g, 0.0603mg/g, 0.0589mg/g, 0.0580mg/g, 0.0602mg/g, and RSD was 4.88%, respectively.
Example 4 thin layer identification of Acanthopanax gracilistylus
Preparing a test solution by taking 100ml of fire therapy Yi formulation liniment, evaporating to dryness, adding 10ml of water into residue for dissolving, shaking and extracting with chloroform for 2 times (5 ml each time), combining chloroform solutions, evaporating to dryness, adding 1ml of methanol into residue for dissolving, taking 2.1g of acanthopanax root as a reference medicinal material for preparing a reference medicinal material solution, preparing a preparation according to a fire therapy Yi formulation liniment preparation process, and preparing the reference medicinal material solution according to a test solution preparation method.
Control solution preparation method comprises collecting control of Isoxazine sneeze, adding methanol to obtain solution containing lmg per 1ml
The negative control solution is prepared by taking the rest medicinal materials except for Acanthopanax gracilistylus according to the formula components, preparing YIFANG liniment without Acanthopanax gracilistylus for fire therapy according to the process requirements, and preparing the negative control solution according to the preparation method of test solution
Silica gel G thin layer plate under thin layer condition
Dispensing 10ul of each of the negative control solutions of the reference medicinal material solution and the reference solution of the sample solution, developing with chloroform-methanol (21:1), and inspecting under an ultraviolet lamp (365nm)
As a result, in the chromatogram of the test sample 4, spots of the same color appear in the chromatogram of the test sample at the positions corresponding to the chromatograms of the reference drug and the reference substance, and the negative reference chromatogram of acanthopanax has no interference at the corresponding positions, so the income standard is met.
Example 5 Ledebouriella seseloides layer authentication
Preparing test solution by taking 90ml of Yi liniment for fire therapy, evaporating to dryness, and dissolving residue with 10ml of ethanol; the reference medicinal solution is prepared by taking 1.5g of radix Saposhnikoviae as reference medicinal material, making into preparation according to the process for preparing liniment for fire therapy, and making into reference medicinal solution according to the preparation method of test solution.
Preparing negative control solution by taking the rest medicinal materials except radix Saposhnikoviae according to prescription composition, making into YIFANG liniment without Acanthopanax fire therapy according to process requirement, and making into negative control solution according to test solution preparation method
Thin layer condition silica gel G thin layer plate, sample amount sample solution 10ul each of negative control solution of control medicinal material solution
Developing solvent trichloromethane-methanol (6:1)
The inspection device is arranged under an ultraviolet lamp (365nm) (sprayed with 10 percent ethanol sulfate solution)
In the result chromatogram of the test sample 5, spots with the same color appear at the corresponding positions of the chromatogram of the control drug, and the windproof negative control chromatogram has no interference at the corresponding positions, so the income standard is met.
Example 6 thin layer identification of cortex Mori
The test solution is prepared by collecting 100ml of Yi formulation liniment for fire therapy, and steaming to 2 ml.
The reference medicinal solution is prepared by preparing 1g of cortex Mori reference medicinal material, making into preparation according to YI prescription liniment preparation process for fire therapy, and making into reference medicinal solution according to test solution preparation method.
The cortex mori negative control solution is prepared according to the formula composition, the rest medicines except the cortex mori are taken to prepare the Yi prescription liniment without the cortex mori for fire therapy according to the process requirements, and the negative control solution is prepared according to the preparation method of the test solution.
Silica gel G thin layer plate under thin layer condition
The sample amount of the test solution is 10ul each of the negative control solutions of the control medicinal material solution, and the developing agent chloroform-methanol (5:1)
Ultraviolet lamp of inspection device (365nm)
In the result chromatogram of the test sample 6, spots with the same color appear at the corresponding positions of the chromatogram of the reference drug, and the cortex mori negative reference chromatogram has no interference at the corresponding positions, so the income standard is met.
Example 7 elderberry thin layer identification
Preparing test solution by taking 100ml of Yi prescription liniment for fire therapy, evaporating to dryness, dissolving the residue with 1ml of methanol
The reference medicinal solution is prepared by preparing 1g of pawpaw reference medicinal material according to the Yi prescription liniment preparation process for fire therapy, and preparing the reference medicinal solution according to the test solution preparation method.
Preparing fructus Chaenomelis negative control solution according to formula composition, taking the rest medicinal materials except fructus Chaenomelis, making into YIFANG liniment without fructus Chaenomelis for fire therapy according to process requirements, and making into negative control solution according to test solution preparation method
Silica gel G thin layer plate under thin layer condition
The sample amount of the test solution is 10ul each of the negative control solutions of the control medicinal material solution, and the developing agent cyclohexane-ethyl acetate-methanol (6:2:1)
Ultraviolet lamp of inspection device (365nm)
In the result chromatogram 7 of the test sample, spots with the same color appear at the corresponding positions of the chromatogram of the reference drug, and the negative reference chromatogram of elderberry has no interference at the corresponding positions, so the income standard is met.
Claims (8)
1. A detection method of a fire therapy liniment is characterized by comprising the following steps: the raw material medicines of the liniment comprise cortex acanthopanacis, myrrh, radix sileris, pawpaw, cortex mori radicis, rhizoma anemones Raddeanae, gynura segetum, elderberry, illicium simonsii and borneol, and the preparation method of the fire therapy liniment comprises the following steps: pulverizing the raw materials except the borneol to obtain medicinal powder, medicinal powder and borneol, and extracting with 50-70% ethanol to obtain a liniment; it comprises the UPLC detection content of the cimicidin:
using the cimicidin as a reference substance; the detection wavelength is 325 nm;
a chromatographic column: c18 as stationary phase
Mobile phase: acetonitrile: 0.05 to 0.2 percent of phosphoric acid
2. The detection method according to claim 1, characterized in that: the phosphoric acid concentration is selected from 0.1%.
3. The detection method according to claim 1, characterized in that: the dimensions of the column were as follows: 2.1X 100mm, 1.8 μm.
4. The detection method according to claim 1, characterized in that: preparation of test solution in UPLC: drying liniment, and extracting with methanol.
5. The detection method according to claim 1, characterized in that: the method comprises the following thin-layer detection contents of elderberry:
(1) collecting liniment, removing solvent, and dissolving the residue with methanol to obtain test solution;
(2) extracting ramulus Sambuci Williamsii reference medicinal material by liniment preparation method, removing solvent from the extractive solution, and extracting with methanol to obtain ramulus Sambuci Williamsii reference medicinal material solution;
(3) the gel was developed on silica gel G thin layer plates with cyclohexane-ethyl acetate-methanol ═ 6:2: 1.
6. The detection method according to claim 1, characterized in that: the method comprises the following thin-layer detection contents of the white mulberry root-bark:
(1) collecting liniment, removing solvent, and dissolving the residue with methanol to obtain test solution;
(2) extracting cortex Mori with reference to the liniment preparation method, removing solvent from the extractive solution, and extracting with methanol to obtain cortex Mori reference solution;
(3) chloroform-methanol 5:1 was applied to silica gel G thin layer plates.
7. The detection method according to claim 1, characterized in that: the method comprises the following thin-layer detection contents of cortex acanthopanacis:
(1) removing solvent from liniment, extracting with water-chloroform solvent system, removing volume of chloroform extractive solution, and dissolving with methanol to obtain test solution;
(2) taking a cortex acanthopanacis reference medicinal material, extracting according to the preparation method of the liniment, and preparing a cortex acanthopanacis reference medicinal material solution according to the content in the step (1);
(3) chloroform-methanol was applied at 21:1 on silica gel G thin layer plates.
8. The detection method according to claim 1, characterized in that: the method comprises the following detection contents of a windproof thin layer:
(1) taking liniment, removing solvent, dissolving with ethanol, and making into test solution;
(2) taking a radix sileris reference medicinal material, extracting according to the preparation method of the liniment, and preparing a radix sileris reference medicinal material solution according to the content in the step (1);
(3) chloroform-methanol 6:1 was developed on silica gel G thin layer plates.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110455689.7A CN113203808A (en) | 2021-04-27 | 2021-04-27 | Detection method of fire therapy liniment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110455689.7A CN113203808A (en) | 2021-04-27 | 2021-04-27 | Detection method of fire therapy liniment |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113203808A true CN113203808A (en) | 2021-08-03 |
Family
ID=77028844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110455689.7A Pending CN113203808A (en) | 2021-04-27 | 2021-04-27 | Detection method of fire therapy liniment |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113203808A (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1778383A (en) * | 2004-11-24 | 2006-05-31 | 香港赛马会中药研究院有限公司 | Herbal medical preparation for the treatment of arthritis |
CN102151322A (en) * | 2010-02-11 | 2011-08-17 | 张金荣 | Chinese medicine composition for treating cold in children, preparation method and detection method thereof |
CN105758985A (en) * | 2016-02-23 | 2016-07-13 | 广州康和药业有限公司 | Quality inspection method of Tongkang tablets |
CN105806964A (en) * | 2014-12-30 | 2016-07-27 | 洛阳惠中兽药有限公司 | Method for detecting Acanthopanax senticosus and Glycyrrhiza uralensis preparation and application thereof |
CN106198837A (en) * | 2016-06-30 | 2016-12-07 | 株洲千金药业股份有限公司 | The quality determining method of old cough with asthma sheet |
CN107688067A (en) * | 2017-09-28 | 2018-02-13 | 株洲千金药业股份有限公司 | The content assaying method of TONGXIAO BIYAN PIAN |
CN109932453A (en) * | 2019-04-10 | 2019-06-25 | 康美(北京)药物研究院有限公司 | A kind of detection method of radix saposhnikoviae |
-
2021
- 2021-04-27 CN CN202110455689.7A patent/CN113203808A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1778383A (en) * | 2004-11-24 | 2006-05-31 | 香港赛马会中药研究院有限公司 | Herbal medical preparation for the treatment of arthritis |
CN102151322A (en) * | 2010-02-11 | 2011-08-17 | 张金荣 | Chinese medicine composition for treating cold in children, preparation method and detection method thereof |
CN105806964A (en) * | 2014-12-30 | 2016-07-27 | 洛阳惠中兽药有限公司 | Method for detecting Acanthopanax senticosus and Glycyrrhiza uralensis preparation and application thereof |
CN105758985A (en) * | 2016-02-23 | 2016-07-13 | 广州康和药业有限公司 | Quality inspection method of Tongkang tablets |
CN106198837A (en) * | 2016-06-30 | 2016-12-07 | 株洲千金药业股份有限公司 | The quality determining method of old cough with asthma sheet |
CN107688067A (en) * | 2017-09-28 | 2018-02-13 | 株洲千金药业股份有限公司 | The content assaying method of TONGXIAO BIYAN PIAN |
CN109932453A (en) * | 2019-04-10 | 2019-06-25 | 康美(北京)药物研究院有限公司 | A kind of detection method of radix saposhnikoviae |
Non-Patent Citations (4)
Title |
---|
上海市药品监督管理局: "《上海市中药饮片炮制规范》", 28 February 2019, 上海科学技术出版社 * |
湖南省食品药品监督管理局: "《湖南省中药材标准 2009年版》", 28 February 2010, 湖南科技出版社 * |
程环等, 辽宁科技出版社 * |
蔡光先等: "《单味中药超微饮片的质量标准研究》", 31 August 2007, 湖南科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mossa | A study on the crude antidiabetic drugs used in Arabian folk medicine | |
CN104161877B (en) | A kind of for compound traditional Chinese medicine composite preventing and treating newcastle disease and its preparation method and application | |
Girish et al. | Herbal drugs on the liver | |
CN103977368B (en) | A kind of for treating sick Chinese medicine composition of numbness caused by rheumatism cold and heat and preparation method thereof | |
Kumar et al. | Indian medicinal plants used for treatment of rheumatoid arthritis | |
Halder et al. | A review on Urtica dioica L | |
CN112336815A (en) | Anti-aging composition for strengthening body, preventing cancer and conditioning hypertension, hyperglycemia and hyperlipidemia and application thereof | |
Qi et al. | Botanical, traditional use, phytochemical, and toxicological of Arisaematis rhizoma | |
CN102935148A (en) | Chinese medicinal composition for treating breast diseases and preparation method thereof | |
CN101361911A (en) | External skin composition with wrinkle-dispelling function and production method thereof | |
CN109239239B (en) | Traditional Chinese medicine composition for clearing lung, eliminating phlegm, relieving cough and asthma and preparation method and application thereof | |
Gour | Boerhaavia diffusa Linn plant: a review–one plant with many therapeutic uses | |
CN101342249B (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
CN103181961A (en) | Preparation method of flavonoid medicine for treating frostbite | |
CN113203808A (en) | Detection method of fire therapy liniment | |
CN107669726A (en) | Treat the wormwood extract liniment of eczema | |
CN107693696A (en) | A kind of clarification process and method of quality control with the drug extract for dispelling facial acne print effect | |
CN102580042A (en) | Traditional Chinese medicine composition for treating wind-cold type of common cold and preparation method of traditional Chinese medicine composition | |
CN105663649A (en) | Traditional Chinese medicine composition for treating pharyngitis and preparation method thereof | |
CN105030961A (en) | Oculentum for treating eye disease | |
CN104873714A (en) | Menopausal woman syndrome treatment kidney-tonifying and wind evil dispelling climacteric prescription preparation method | |
CN104940513A (en) | Pharmaceutical composition for treating menopause syndrome | |
CN109568496B (en) | Detection method of traditional Chinese medicine composition for treating diabetes | |
CN105311331A (en) | Traditional Chinese medicine composition for treating eczema and preparation method thereof | |
Jaiswal et al. | Aconite: Ethnopharmacological Benefits and Toxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210803 |